Recent aspects on physiopathology of diabetic macular edema;Aspectos atuais na fisiopatologia do edema macular diabéatico

Revista Brasileira de Oftalmologia

Volumn 67, Issue 1, 2008, Pages 45-49

  Dos Santos Motta, Máario Martins ^a   Coblentz, Jacqueline ^b   De Melo, Laura Gomes Nunes ^a,c  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b Faculdade de Medicina de TeresóApolis UNIFESO   (Brazil)

^c HOSPITAL DOS SERVIDORES DO ESTADO   (Brazil)

Author keywords

Diabetes mellitus, type 1 complications; Diabetes mellitus, type 2 complications; Diabetic retinopathy physiopathology; Macular edema

Indexed keywords

EID: 77951888381     PISSN: 00347280     EISSN: 19828551     Source Type: Journal    
DOI: 10.1590/s0034-72802008000100009     Document Type: Article

References (24)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527-32.
2. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552-63.
3. Chew E Y, Ferris III FL. Nonproliferative diabetic retinopathy. In: Ryan SJ, editor. Retina. 5th ed. St. Louis: Mosby; 2006. vol. II, cap. 67, seção 5. P. 1271-84.
4. MinistéArio da SaúAde. Indicadores de morbidade e fatores de risco: D.10 Taxa de prevalência de diabete melito[Internet] [citado 2007 Dez 12]. DisponíAvel em: http://tabnet.datasus. gov. br/cgi/idb2006/d10.htm
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
7. Erratum in: Lancet 1999;354(9178):602.
8. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342(6):381-9.
9. Erratum in: N Engl J Med. 2000;342(18):1376.
10. Augustin AJ, Dick HB, Koch F, Schmidt-Erfurth U. Correlation of blood-glucose control with oxidative metabolites in plasma and vitreous body of diabetic patients. Eur J Ophthalmol. 2002;12(2):94-101.
11. Aiello L P, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46(9):1473-80.
12. PCK-DRS2 Group, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113(12):2221-30.
13. Aiello L P, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-7.
14. Comment in: N Engl J Med. 1994;331(22):1519-20.
15. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.e1-15.
16. Cunningham ET Jr, Adamis A P, Altaweel M, Aiello L P, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747-57.
17. Murphy R P, Nanda M, Plotnick L, Enger C, Vitale S, Patz A. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108(2):215-8.
18. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med. 1983;309(9):527-30.
19. Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35(4):416-20.
20. Chanteleau E, Kohner EM. Why some cases of retinopathy worsen when diabetic control improves. BMJ. 1997;315(7116):1105-6.
21. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, et al. Essential role of growth hormone in ischemiainduced retinal neovascularization. Science. 1997;276(5319):1706-9.
22. Kuwabara T, Cogan DG. Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol. 1963; 69: 492-502.
23. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14(4):223-32.
24. Basteau F, Montermousque B, Aouizerate F. CEdème maculaire diffus de la réAtinopathie diabéAtique et pathologie de l'interface vitréAo-réAtinienne. J Fr Ophtalmol. 2004;27(10):1109-20.